BMS牵手AI制药龙头，全面引入「AI科学家」！
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - Bristol Myers Squibb is expanding its long-running partnership with Schrödinger to deploy the Bunsen AI research-agent platform across all of its global R&D sites, alongside Schrödinger's RetroSynth retrosynthesis planning tool. It signals a large pharma moving AI from pilot computational chemistry into org-wide agentic infrastructure.
- The deal builds on collaboration since 2020, when BMS R&D began routinely using Schrödinger's AI/physics-based computational tools in small-molecule pipelines; Bunsen now goes to every global R&D branch.
- RetroSynth adds high-throughput evaluation of chemical synthesis routes, targeting the synthesis-planning bottleneck rather than just molecule design.
- BMS says AI tools have already cut investigational drug manufacturing time by 20–30% (CRO Robert Plenge projects up to 50%), and credits AI with surfacing an early-clinical sickle cell disease therapy.
- Broader AI buildout: BMS bought a latest-generation NVIDIA enterprise AI supercomputing cluster (claimed first life-sciences company to do so) and in May signed with Anthropic to give 30,000+ employees Claude reasoning/agent capabilities across R&D, clinical, manufacturing, and commercial functions.
Sources (1)
BMS牵手AI制药龙头，全面引入「AI科学家」！
TL;DR - Bristol Myers Squibb is expanding its long-running partnership with Schrödinger to deploy the Bunsen AI research-agent platform across all of its global R&D sites, alongside Schrödinger's RetroSynth retrosynthesis planning tool. It signals a large pharma moving AI from pilot computational chemistry into org-wide agentic infrastructure.
- The deal builds on collaboration since 2020, when BMS R&D began routinely using Schrödinger's AI/physics-based computational tools in small-molecule pipelines; Bunsen now goes to every global R&D branch.
- RetroSynth adds high-throughput evaluation of chemical synthesis routes, targeting the synthesis-planning bottleneck rather than just molecule design.
- BMS says AI tools have already cut investigational drug manufacturing time by 20–30% (CRO Robert Plenge projects up to 50%), and credits AI with surfacing an early-clinical sickle cell disease therapy.
- Broader AI buildout: BMS bought a latest-generation NVIDIA enterprise AI supercomputing cluster (claimed first life-sciences company to do so) and in May signed with Anthropic to give 30,000+ employees Claude reasoning/agent capabilities across R&D, clinical, manufacturing, and commercial functions.